Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin, Capecitabine, and Bevacizumab in Advanced Colorectal Cancer
NCT00159432Phase 2Completed
- Sponsor
- University of Southern California
- Start
- Feb 2005
- Primary completion
- Jun 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab in colorectal cancer (CRC), sponsored by University of Southern California. Primary endpoint: Progression-Free Survival at 6 years. Started Feb 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00159432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00159432.